Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Leukemia and Lymphoma

• Publication date

  2018-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/10428194.2017.1393672PMID 29105525
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis

  2017cited by this paper
• Catalyzing improvements in ALL therapy with asparaginase.

  2017cited by this paper
• DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China

  2016cited by this paper
• Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

  2016cited by this paper
• A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial

  2016cited by this paper
• Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

  2016cited by this paper
• Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy

  2015cited by this paper
• Clinical application of asparaginase activity levels following treatment with pegaspargase

  2015cited by this paper
• How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.

  2014cited by this paper
• Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

  2014cited by this paper
• Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

  2013cited by this paper
• First‐line combination of gemcitabine, oxaliplatin, and L‐asparaginase (GELOX) followed by involved‐field radiation therapy for patients with stage IE/IIE extranodal natural killer/T‐cell lymphoma

  2013cited by this paper
• A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.

  2013cited by this paper
• L‐asparaginase treatment in acute lymphoblastic leukemia

  2011cited by this paper
• Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

  2011cited by this paper
• Treatment of localized extranodal NK/T cell lymphoma, nasal type

  2010cited by this paper
• Phase I study of dexamethasone, methotrexate, ifosfamide, l‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemia

  2008cited by this paper
• Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study

  2008cited by this paper
• Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.

  2007cited by this paper
• Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia

  2006cited by this paper
• A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.

  2006cited by this paper
• Selective apoptosis of natural killer‐cell tumours by l‐asparaginase

  2005cited by this paper
• Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).

  2004cited by this paper
• A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

  2002cited by this paper
• Drug monitoring of low‐dose PEG‐asparaginase (Oncaspartm) in children with relapsed acute lymphoblastic leukaemia

  2001cited by this paper
• Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL‐BFM 95 reinduction treatment

  2001cited by this paper
• CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?

  2001cited by this paper
• Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL‐BFM 95 protocols

  2000cited by this paper
• The Three Asparaginases

  1999cited by this paper
• The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.

  1999cited by this paper
• Frequent expression of P‐glycoprotein/MDR1 by nasal T‐cell lymphoma cells

  1995cited by this paper
• Non-Hodgkin's Lymphomas

  1994cited by this paper
• EVIDENCE THAT THE L-ASPARAGINASE OF GUINEA PIG SERUM IS RESPONSIBLE FOR ITS ANTILYMPHOMA EFFECTS

  1963cited by this paper
• EVIDENCE THAT THE L-ASPARAGINASE OF GUINEA PIG SERUM IS RESPONSIBLE FOR ITS ANTILYMPHOMA EFFECTS

  1963cited by this paper

• Severe Hypertriglyceridemia Secondary to Long-Acting Asparaginase in Pediatric Patients With Acute Lymphoblastic Leukemia.

  2025cites this paper
• PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity

  2018cites this paper
• Gemcitabine/oxaliplatin/pegaspargase

  2018cites this paper